Komipharm International

At a glance

Komipharm International filed 22 disclosures in the last 12 months, including 1 insider and 1 buyback. The most recent key filing was on Oct 27: Outside director bought 4,740 sh on the market, Oct 26.

Revenue for 2025 was ₩52.5B, down 10.7% on 2024. Operating margin was 3.7% against 10.5% a year earlier. Debt was 86% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩28.6B and operating profit of ₩1.9B.

The 2025 annual report lists 172 employees with an average tenure of 7.1 years and average pay of ₩47.1M, #1581 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩108.4M each on average. It paid no cash dividend for 2025. 양경훈 and related parties held 38.36% at year end.

From the 2025 annual report

Staff: 172 (82 men, 90 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩8.1B. Directors and auditors: 7, paid ₩759.1M in total.

No cash dividend was paid for 2025.

Largest shareholder

양경훈 holds 29.88%; with 7 related parties the group holds 38.36% of common shares at year end (from 40.01% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary